Trippa L - Search Results

1

A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.

Wason JM, Trippa L. Wason JM, et al. Among authors: trippa l. Stat Med. 2014 Jun 15;33(13):2206-21. doi: 10.1002/sim.6086. Epub 2014 Jan 14. Stat Med. 2014. PMID: 24421053

2

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.

Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. Mayer EL, et al. Among authors: trippa l. Ann Oncol. 2020 Nov;31(11):1518-1525. doi: 10.1016/j.annonc.2020.08.2064. Epub 2020 Aug 13. Ann Oncol. 2020. PMID: 32798689 Free PMC article. Clinical Trial.

3

Reply to "Keynote 48: Is it really for everyone?".

Schoenfeld JD, Fell G, Haddad RI, Trippa L. Schoenfeld JD, et al. Among authors: trippa l. Oral Oncol. 2021 Apr;115:105108. doi: 10.1016/j.oraloncology.2020.105108. Epub 2020 Dec 1. Oral Oncol. 2021. PMID: 33277202 No abstract available.

4

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. Leone JP, et al. Among authors: trippa l. Breast Cancer Res Treat. 2020 Jan;179(1):113-123. doi: 10.1007/s10549-019-05445-z. Epub 2019 Sep 20. Breast Cancer Res Treat. 2020. PMID: 31541381 Clinical Trial.

5

Optimality of testing procedures for survival data in the nonproportional hazards setting.

Arfè A, Alexander B, Trippa L. Arfè A, et al. Among authors: trippa l. Biometrics. 2021 Jun;77(2):587-598. doi: 10.1111/biom.13315. Epub 2020 Jun 24. Biometrics. 2021. PMID: 32535892

6

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Ghobrial IM, et al. Among authors: trippa l. Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31456261 Clinical Trial.

7

Bayesian enrichment strategies for randomized discontinuation trials.

Trippa L, Rosner GL, Müller P. Trippa L, et al. Biometrics. 2012 Mar;68(1):203-11. doi: 10.1111/j.1541-0420.2011.01623.x. Epub 2011 Jun 29. Biometrics. 2012. PMID: 21714780 Free PMC article.

8

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Trippa L, et al. J Clin Oncol. 2012 Sep 10;30(26):3258-63. doi: 10.1200/JCO.2011.39.8420. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649140 Free PMC article.

9

Bayesian designs and the control of frequentist characteristics: a practical solution.

Ventz S, Trippa L. Ventz S, et al. Among authors: trippa l. Biometrics. 2015 Mar;71(1):218-226. doi: 10.1111/biom.12226. Epub 2014 Sep 5. Biometrics. 2015. PMID: 25196832

10

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Trippa L, et al. Neuro Oncol. 2015 Aug;17(8):1106-13. doi: 10.1093/neuonc/nou345. Epub 2015 Jan 7. Neuro Oncol. 2015. PMID: 25568226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results